Target intelligence / Profile preview

Host intestinal epithelial innate immune and barrier pathways

Molecular classification
Other
01

Overview

The host intestinal epithelial innate immune and barrier pathways represent a complex system of physical, chemical, and cellular components that maintain gut homeostasis and protect against pathogens. The physical barrier is primarily composed of a single layer of epithelial cells connected by tight junction proteins like claudins and occludins, which regulate paracellular permeability (Nature Reviews Gastroenterology & Hepatology, 2021). The innate immune component involves pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) and NOD-like receptors (NLRs) that sense microbial signals and trigger protective responses, including the secretion of antimicrobial peptides and mucins (Frontiers in Immunology, 2020). Dysregulation of these pathways is a hallmark of inflammatory bowel diseases (IBD), where increased permeability and aberrant immune activation lead to chronic inflammation (Science, 2017). Therapeutic strategies often target specific molecules within these pathways, such as TNF-alpha or JAK kinases, to restore barrier integrity and dampen excessive immune responses (The Lancet, 2019). Emerging therapies also focus on directly enhancing barrier function through the modulation of tight junction proteins or the administration of growth factors like GLP-2 (Gastroenterology, 2022).

Other names
Intestinal epithelial barrierGut mucosal immunityIntestinal innate immune systemMucosal barrier pathways
02

Mechanism of action

Modulation of cytokine signaling, inhibition of leukocyte trafficking, and reinforcement of epithelial tight junction integrity.

03

Biological functions

Immune responseBarrier functionSignal transductionCell-cell adhesionHomeostasis
04

Disease associations

Inflammatory bowel diseaseCrohn's diseaseUlcerative colitisCeliac diseaseInfection
05

Safety considerations

Increased risk of opportunistic infectionsPotential for malignancy with long-term immunosuppressionImpaired mucosal wound healing
06

Interacting drugs

Vedolizumab

5 more in the full profile.

07

Biomarkers

Fecal calprotectinZonulinIntestinal fatty acid-binding protein (I-FABP)C-reactive protein

Beyond the preview

Go deeper on Host intestinal epithelial innate immune and barrier pathways.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Host intestinal epithelial innate immune and barrier pathways.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call